Поисковый запрос: (<.>S=АНТИТЕЛА К ФАКТОРУ НЕКРОЗА ОПУХОЛИ<.>) |
Общее количество найденных документов : 18
Показаны документы с 1 по 18
|
1.
| Van Hogezand R.A. New therapies for inflammatory bowel disease: An update on chimeric anti-TNF'альфа' antibodies and IL-10 therapy // Scand. J. Gastroenterol., 1997. Vol. 32, Suppl. n 223.-С.105-107
|
2.
| Van Hogezand R.A. New therapies for inflammatory bowel disease: An update on chimeric anti-TNF'альфа' antibodies and IL-10 therapy // Scand. J. Gastroenterol., 1997. Vol. 32, Suppl. n 223.-С.105-107
|
3.
| Leeb B.F. Anti-TNF-'альфа'-Therapie als neue Option in der Behandlung der rheumatoiden Arthritis? // Wien. med. Wochenschr., 1999. Vol. 149, N 19-20.-С.554-557
|
4.
| Leeb B.F. Anti-TNF-'альфа'-Therapie als neue Option in der Behandlung der rheumatoiden Arthritis? // Wien. med. Wochenschr., 1999. Vol. 149, N 19-20.-С.554-557
|
5.
| Leeb B.F. Anti-TNF-'альфа'-Therapie als neue Option in der Behandlung der rheumatoiden Arthritis? // Wien. med. Wochenschr., 1999. Vol. 149, N 19-20.-С.554-557
|
6.
| Leeb B.F. Anti-TNF-'альфа'-Therapie als neue Option in der Behandlung der rheumatoiden Arthritis? // Wien. med. Wochenschr., 1999. Vol. 149, N 19-20.-С.554-557
|
7.
| Maini R.N. The 2005 International Symposium on Advances in Targeted Therapies: What have we learned in the 2000s and where are we going? // Ann. Rheum. Diseases, 2005. Vol. 64, прил. 4.-С.106-108
|
8.
| Maini R.N. The 2005 International Symposium on Advances in Targeted Therapies: What have we learned in the 2000s and where are we going? // Ann. Rheum. Diseases, 2005. Vol. 64, прил. 4.-С.106-108
|
9.
| Grunke M. Successful treatment of inflammatory knee osteoarthritis with tumour necrosis factor blockade // Ann. Rheum. Diseases, 2006. Vol. 65, N 4.-С.555-556
|
10.
| Grunke M. Successful treatment of inflammatory knee osteoarthritis with tumour necrosis factor blockade // Ann. Rheum. Diseases, 2006. Vol. 65, N 4.-С.555-556
|
11.
| Why are only 50% of courses of anti-tumor necrosis factor agents continued for only 2 years in some settings? Need for longterm observations in standard care to complement clinical trials // J. Rheumatol., 2006. Vol. 33, N 12.-С.2372-2375
|
12.
| No change of serum levels of leptin and adiponectin during anti-tumour necrosis factor antibody treatment with adalimumab in patients with rheumatoid arthritis // Ann. Rheum. Diseases, 2006. Vol. 65, N 7.-С.970-971
|
13.
| No change of serum levels of leptin and adiponectin during anti-tumour necrosis factor antibody treatment with adalimumab in patients with rheumatoid arthritis // Ann. Rheum. Diseases, 2006. Vol. 65, N 7.-С.970-971
|
14.
| No change of serum levels of leptin and adiponectin during anti-tumour necrosis factor antibody treatment with adalimumab in patients with rheumatoid arthritis // Ann. Rheum. Diseases, 2006. Vol. 65, N 7.-С.970-971
|
15.
| Turk Method for treating multiple sclerosis
|
16.
| Turk Method for treating multiple sclerosis
|
17.
| Turk Method for treating multiple sclerosis
|
18.
| Turk Method for treating multiple sclerosis
|
|
|
Главная
Назад
"Электронные каталоги и базы данных библиотек СО РАН"